Morningstar: Interim Results Show XL184's Benefit in Ovarian and Prostate Cancer |
In a cohort of patients with ovarian cancer, tumor shrinkage was observed in 81% of patients, and stable disease was reported in 48% of patients. The overall week-12 disease control rate, or DCR, was 64%. Furthermore, in a subset analysis, the activity of XL184 in both platinum-sensitive and platinum-resistant/refractory cancer was also very promising. In a cohort of patients with prostate cancer, 95% of patients achieved complete or partial resolution of metastatic bone lesions. For soft tissue lesions, tumor shrinkage was observed in 69% of patients, and stable disease was reported in 74% of cases. The week-12 DCR in the prostate cancer cohort was 71%. No major safety issues were observed in either trial.
Exelixis is studying its lead drug candidate, XL184, across a broad range of tumor types, and the drug has demonstrated anti-tumor activity in nine of 12 indications studied to date. The week-12 DCR for the overall population was 49%, with the highest rates occurring in liver cancer, prostate cancer, and ovarian cancer.
No comments:
Post a Comment